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Lung cancer is one of the most commonly diagnosed cancer and despite therapeutic
advances, mortality remains high. The long period of clinical latency associated with
lung cancer provides an ideal window of opportunity to administer vaccines to at-risk
individuals that can prevent tumor progression and initiate long-term anti-tumor immune
surveillance. Here we describe a personalized vaccination regime that could be applied
for both therapeutic and prophylactic prevention of lung cancer, based on the derivation
of lung cancer cells from induced pluripotent stem cells. Stem cells from healthy
mice were modified to express Cre-dependent KRASG12D and Trp53R172H prior to
differentiation to lung progenitor cells. Subsequent viral delivery of Cre caused activation
of exogenous driver mutations, resulting in transformation and development of lung
cancer cells. iPSC-derived lung cancer cells were highly antigenically related to lung
cancer cells induced in LSL-KRASG12D/+; Trp53R172H/+ transgenic mice and were
antigenically unrelated to original pluripotent stem cells or pancreatic cancer cells derived
using the same technological platform. For vaccination, induced lung cancer cells were
infected with oncolytic Adenovirus or Vaccinia virus, to act as vaccine adjuvants, prior
to delivery of vaccines sequentially to a murine inducible transgenic model of lung
cancer. Application of this Virus-Infected, Reprogrammed Somatic cell-derived Tumor
cell (VIReST) regime primed tumor-specific T cell responses that significantly prolonged
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survival in both subcutaneous post-vaccine challenge models and induced transgenic
models of lung cancer, demonstrating that stem cell-derived prophylactic vaccines may
be a feasible intervention for treatment or prevention of lung cancer development in
at-risk individuals.
Keywords: lung cancer, vaccine, induced pluripotent stem cells, KRAS, TP53, adenovirus, Vaccinia virus,
neo-antigen
INTRODUCTION
Lung cancer remains one of the most fatal malignant tumors.
The 2018 GLOBOCAN report suggested that lung cancer is the
most commonly diagnosed cancer (11.6% of total cases) and
the leading cause of cancer death (18.4% of total cancer deaths)
(1) and despite advances in therapeutic approaches, the 5 year
survival rate is 16% for the majority of patients whose tumor is
not diagnosed at an early, localized stage (2).
Recent immunotherapeutic approaches for the treatment
of lung cancer have investigated therapeutic vaccination as
a method of controlling disease progression. Theoretically,
vaccination strategies are a promising therapeutic option as they
can provoke an anergic immune system to activation against one
or more tumor cell antigens, resulting in a long-term immune
response against the tumor. The majority of these approaches
have their basis in targeting specific tumor associated antigens
(TAAs) such as epidermal growth factor receptor (EGFR), over-
expressed in over half of lung cancer cases, which has been
targeted using Cimavax-EGF, an immunogenic recombinant
protein vaccine orMucin-1 (MUC1), also over-expressed in non-
small cell lung cancer using Simuvax, a liposomally delivered
MUCI peptide. Despite promising early data, these agents
have yet to meet primary endpoints in late phase trials (3,
4). TG4010, an alternative MUCI-based vaccine, delivered
using a Vaccinia virus (VV) platform is more promising, and
evidence of epitope spreading beyond the primary target epitope
has been observed clinically (5). The targeting of multiple
epitopes will be crucial for successful vaccination strategies
to prevent tumor escape from control, however a phase III
study investigating a whole cell allogeneic vaccination approach
has also failed to demonstrate improved survival (6). The
paucity of success of therapeutic vaccination strategies across
all cancers can be ascribed to a suboptimal vaccine design,
in which inappropriate antigens are targeted or adjuvants
are ineffective at breaking immunological tolerance to tumor
antigens, and their application in advanced stage disease in which
the tumor microenvironment is highly immunosuppressive and
refractory to intervention (7). Targeting early pre-malignant
lesions, however, may demonstrate more success. These lesions
are heavily infiltrated by both adaptive and innate immune
cells, with activated phenotypes, suggesting on-going immune
responses. Furthermore, immunosuppressive cells are rare at this
stage (7).
Recent data suggests a long period of clinical latency of
at least 20 years before clinical detection of lung cancer (8).
Analysis of the accrual of mutations during lung cancer evolution
suggests that lung adenocarcinomas may be particularly suited
for early intervention using prophylactic, as opposed to
therapeutic vaccination strategies as accrual of known non-
synonymous mutations, particularly driver mutations, occur as
early molecular events, and 76% of all mutations were detected in
all regions of the tumor (9).
We have recently presented a novel, personalized prophylactic
vaccination strategy for the prevention of pancreatic ductal
adenocarcinoma (PDAC) development in which induced
pluripotent stem cells (iPSCs) were induced to PDAC cells via
stable knock-in of inactive KRASG12D and p53R172H prior to
lineage differentiation and transformation (10). Importantly,
we found that the derived murine tumor cells displayed high
antigenic similarities to PDAC cell lines derived from the related
KPC or KC transgenic mouse model, demonstrating that the
process we used to generate autologous vaccination material
was sufficient to model neo-antigen accrual, based on the
genetic and epigenetic profile of autologous stem cells, during
the earliest stages of tumorigenesis. When pre-infected with
replicating oncolytic Adenovirus (AdV) and Vaccinia virus
(VV), to act as potent immune adjuvants, and administered
to pre-malignant animals in a prime-boost Virus-Infected
Reprogrammed Somatic cell-derived Tumor cell vaccination
(VIReST) regime, we were able to significantly delay disease
development in a robust transgenic mouse model of disease,
extending life-span of prophylactically vaccinated animals
by up to 51%. Given the latency associated with lung cancer
development, in addition to the early and homogenous
accrual of truncal mutations, we reasoned that lung cancer
would also be particularly responsive to prophylactic therapy.
Here we present a VIReST regime targeting lung cancer, in
which iPSCs from healthy animals were modified to express
inactivated common driver mutations KRASG12D and p53R172H
(11), prior to differentiation into lung progenitor cells and
transformation to tumor cells. The iPSC derived lung cancer
cell line was able to mimic the characteristics of the lung
cancer cell line established from an early-stage lung cancer
model. Pre-infection of these cells with AdV and VV prior
to delivery into pre-malignant animals was able to induce
potent anti-tumor immune responses that safely delayed
tumor development when administered prophylactically using
a subcutaneous murine model of lung cancer and when
administered prior to disease detection in a complex transgenic
model of disease. These data suggest VIReST as an effective
alternative to autologous whole cancer cell vaccines, that
can be delivered prior to or early in disease development, is
antigenically compatible with each patient and can engage
immune surveillance mechanisms to detect initiation of
lung malignancies.
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MATERIALS AND METHODS
Cells and Viruses
Murine embryonic fibroblasts (MEFs) from E13.5 WT mice
were cultured using Dulbecco’s modified Eagles medium
(DMEM) supplemented with 10% fetal bovine serum (FBS).
MEF feeder cells were inactivated by mitomycin C (MMC)
(10µg/ml for 2.5 h) (MedChemExpress, HY-13316) treatment.
iPSCs were cultured using mES medium (DMEM supplemented
with 15% FBS (Gemini, 900–108), leukemia inhibitory factor
(LIF) (10 ng/ml) (Thermo Fisher Scientific, PMC9484), β-
mercaptoethanol (0.1mM) (Sigma Aldrich, 60-24-2), 1x non-
essential amino acids (NEAA) (Thermo Fisher Scientific,
11140050), 1x Glutamax (Thermo Fisher Scientific, 35050061),
Sodium pyruvate (1mM) (Thermo Fisher Scientific, 11360070).
The LC cell lines KPL 160302S and KPL 160424S were
cultured from LSL-KRASG12D/+; Trp53R172H/+ mice that
had developed lung cancer after Ad-Cre inhalation. These
were maintained in DMEM supplemented with 10% FBS.
CV1 (African monkey kidney) cells and JH293 cells were
obtained from the American Type Culture Collection (ATCC,
VA, USA) and maintained in DMEM containing 10% FBS. KP-
LC cells were maintained in DMEM containing 10% FBS. The
PDAC cell line TB11381 was cultured from LSL-KRASG12D/+;
Trp53R172H/+; Pdx-1-Cre mice that had developed PDAC (12).
This was kindly provided by David Tuveson (Cancer Research
UKCambridge Institute, now at Cold Spring Harbor Laboratory)
and maintained in DMEM supplemented with 10% FBS. Mouse
Ovarian Surface Epithelial Cell Line (MOSEC) was provided by
Prof Iain McNeish at Barts Cancer Institute and maintained in
DMEM supplemented with 10% FBS. All cell lines were routinely
tested for the presence of mycoplasma. Cell lines used or created
during this study are listed in Table S1.
The thymidine kinase (TK)-deleted Lister strain Vaccinia
virus (VVL15) was described previously (13). VVL15 was
further modified by XhoI/EcoRI-mediated removal of the
LacZ open reading frame (ORF) from the VV TK shuttle
vector pSC65 (GenBank: HC193923.1), which was replaced
with red fluorescent protein (RFP) derived by NheI/AflII
digestion of pCMV-dsRED-Express (Clontech). The virus was
produced as previously described (14). Ad-Cre non-replicative
virus was purchased from Vector Biolabs and propagated in
our laboratory. Wild-type Adenovirus serotype 5 (Ad5) was
described previously (15).
Teratoma Test
A total 1 × 107 of LSL-KRASG12D/+; LSL-Trp53R172H/+ iPSCs
were implanted subcutaneously into the right flank of nude male
mice. After 2 weeks and 4 days, with diameter of<1.5 cm, tumors
were surgically dissected, formalin-fixed, paraffin-embedded, and
stained using hematoxylin and eosin (H&E).
Induction of LSL-KRASG12D/+;
LSL-Trp53R172H/+ iPSCs to Lung Cancer
Cells
LSL-KRASG12D/+; LSL-Trp53R172H/+ iPSCs were cultured on
mouse embryonic fibroblasts (MEF) in-mES medium. iPSCs
were treated with 0.25% trypsin for 5min, and the differential
adhesion method was used to remove MEF. The basic
medium of induction was serum-free differentiation (SFD)
media of DMEM/F12 (3:1) (Thermo Fisher Scientific, 11765054)
supplemented withN2 (Thermo Fisher Scientific, 17502048), B27
(Thermo Fisher Scientific, 12587010), ascorbic acid (50µg/ml)
(Sigma Aldrich), Glutamax (2mM) (Thermo Fisher Scientific,
35050061), monothioglycerol (0.4µM) (Sigma Aldrich, 96-
27-5), 0.05% bovine serum albumin (BSA) (Sangon Biotech,
9048-46-8), 1% penicillin-streptomycin. iPSCs were plated
onto six-well plates coated by 1% agar to form embryoid
bodies in the media of SFD with Y-27632 (10µM) (R&D
Systems, 129830-38-2) and mouse BMP4 (3 ng/ml) (R&D
Systems, 5020-BP) for 24 h. Embryoid bodies were induced
to endoderm in SFD with Y27632 (10µM), mouse BMP4
(0.5 ng/ml), mouse bFGF (2.5 ng/ml) (R&D Systems, 3139-
FB), mouse Activin A (100 ng/ml) (PeproTech, 120-14) for
72 h on low-adherence plates. Half of the old media was
removed, and half new media was added every 36 h. Endodermal
cells were then induced to anterior foregut endoderm. Cells
were cultured on 0.2% Gelatin-coated, 24-well plates (100,000–
150,000 cells/well) in SFD with Dorsomorphin dihydrochloride
(1.5µM) (R&D Systems, 1219168-18-9) and SB431542 (10µM)
(R&D Systems, 301836-41-9) for 24 h, followed by SFD with
SB431542 (10µM) and IWP2 (1µM) (R&D Systems,686770-
61-6) for 24 h. Cells were induced to lung progenitors in
the medium of SFD with CHIR99021 (3µM) (Stemgent,04-
0004-10), mouse FGF10 (10 ng/ml) (R&D Systems, 6224-FG-
025), mouse FGF7 (10 ng/ml) (R&D Systems, 5028-KG-025),
mouse BMP4 (10 ng/ml) (R&D Systems, 5020-BP), and all-trans
retinoic acid (ATRA) (1µM) (Sigma, 302-79-4) for 9 days.
The differentiation protocol was based on a previous report
(16). On the 10th day of lung progenitor differentiation, non-
replicative Ad5-Cre was added at 50 PFU/cell to remove the LSL
cassette. After continuous passage, lung progenitors transformed
into lung cancer cells. The changes in cell morphology at each
stage of induced differentiation were photographed using the
light microscope.
Immunofluorescence
At each differentiation stage, cells were fixed with 4% PFA for
15min at room temperature then washed three times with
PBS. The slides of cells were permeabilized with PBS + 0.5%
Triton X-100 for 20min and washed three times with PBS. Slides
were blocked with 10% goat serum for 30min and incubated
with the primary antibodies at 4◦C overnight (>16 h) diluted
in PBS. Following incubation, the slides were rinsed with PBS
and incubated with secondary antibodies at 37◦C for 1 h. The
slides were rinsed with PBS and the cell nucleus was stained
with DAPI (Sigma Aldrich). The images were visualized using
an Olympus BX41 fluorescence microscope. Dilutions and
Catalog numbers for primary antibodies were as follows: Anti-
Oct4 antibody (1:200 dilution) (Abcam, ab18976), Anti-Nanog
antibody (1:200 dilution) (Abcam, ab80892), Anti-FOXA2
antibody (1:300 dilution) (Abcam, ab108422), Anti-SOX17
antibody (1:50 dilution) (Abcam, ab191699), Human/Mouse/Rat
SOX2 antibody (1:200 dilution) (R&D Systems, AF2018),
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Anti-TTF1 antibody (1:200 dilution) (Abcam, ab76013),
Anti-SOX9 antibody (1:200 dilution) (Abcam, ab26414). The
secondary antibody: Goat Anti-Rabbit IgG H&L (Alexa Fluor
488) (1:500 dilution) (Abcam, ab150077), Rhodamine (TRITC)-
conjugated AffiniPure Bovine Anti-Goat IgG (H+L) (1:100
dilution) (Jackson ImmunoResearch, 805-025-180).
Quantitative Real-Time PCR
At each differentiation stage, total RNA was extracted using
Trizol (Invitrogen) and cDNA was synthesized by HiScript Q
Select RT SuperMix for qPCR (+gDNA wiper) kit (Vazyme,
R133-01). qPCR was carried out using the ABI STEPONE
PLUS system and the AceQTM qPCR SYBR Green Master Mix
(Vazyme, Q111-02). The primers used are listed in Table S2.
Identification of Loxp-Stop-Loxp Cassette
Removal After Ad5-Cre Addition
Cells were collected and digested in 500 µl/ tube digestion buffer
[distilled water + 50mM Tris-HCl (PH 8.0) + 100mM EDTA
(PH8.0) + 100mM NaCl + 1% SDS] + 0.1 mg/ml proteinase K
for 30min at 55
◦
C. Cells were then added 250 µl/ tube saturated
NaCl solution and 100 µl chloroform and centrifuged 13,523 g at
4
◦
C for 10min. The upper supernatant was transferred to another
tube and 500 µl isopropanol added prior to centrifugation at
13,523 g for 10min. The supernatant was discarded and 250 µl
70% alcohol was added for 10min. The tubes were centrifuged
13,523 g for 5min. The supernatant was discarded and distilled
water was added to dissolve the DNA. DNA concentration was
measured using the Nanodrop (Thermo Fisher).
Primers on the both sides of LSL cassette were designed. The
bands of activated mutations of KRAS/Trp53 were longer than
the bands of wide type with one loxp. The fragments with the
complete LSL cassettes cannot be amplified in this PCR system.
Primers for KRAS identification: F: 5′-ATATCCAGTCAACAA
AGAATACC-3′, R: 5′-TCCGAATTCAGTGACTACAGATGT
ACAGAG-3′
Primers for p53 identification: F: 5′-AGCCTGCCTAGCTTCC
TCAGG-3′, R: 5′-CTTGGAGACATAGCCACACTG-3′.
Karyotype Analysis
WT iPSC/KP-LC/KPL 160302S/KPL 160424S were cultured to a
density of about 80–90%, and treated with colchicine (0.2µg/ml)
for 3 h. Cells were digested with trypsin and collected into
centrifuge tubes, pipetted into single cell suspensions, centrifuged
at 250 g for 5min and the supernatant was discarded. Five
milliliters 37◦C preheated KCl solution (0.075 mol/L) was added.
The cell suspensions were mixed uniformly, and the hypotonic
treatment performed in the 37◦C water bath for 30min. The cell
suspensions were centrifuged and the supernatant discarded. The
cell pellets were resuspended with a little residual liquid. One
milliliter fixative solution (methanol: glacial acetic acid = 3: 1)
was added slowly along the tube wall. The cell suspensions were
mixed while dropping, and left to stand for 5min. Afterwards,
the cell suspensions were centrifuged, and the supernatant
was discarded. Three milliliters fixative solution was added,
and left to stand for 30min. Again, the cell suspensions were
centrifuged, and the supernatant was discarded. Three milliliters
fixative solution was added, and left to stand for 30min. The
cell suspensions were centrifuged, and the supernatant was
discarded. Onemilliliter fixative solution was added, and the cells
were pipetted to make cell suspensions. The cell suspension was
aspirated with a pipette and dropped on cold glass slides at high
altitude. The slides were baked in an oven at 80◦C for 2 h, digested
by preheating trypsin for 30 s, stained by Giemsa for 10min,
rinsed with water, and dried. Finally, the slides were observed and
pictured with oil lens.
Transcriptome Sequencing
Cell transcriptomes were sequenced in BGI. Tec, Shenzhen,
China. RNA libraries were prepared using an Illumina TruSeq
RNA Sample Prep Kit. Briefly, 200 ng total RNA sample was
purified by oligo-dT beads, then poly (A)-containing mRNA
were fragmented into small pieces with Elute, Prime, Fragment
mix. First-strand cDNA was generated by First Strand Master
Mix and Super Script II (Invitrogen) reverse transcription. The
Second Strand Master Mix was added to synthesize second-
strand cDNA (16◦C for 1 h). The purified fragmented cDNA was
combined with end-repair mix and incubated at 30◦C for 30min.
The end-repaired DNA was purified using Ampure XP Beads
(AGENCOURT). A-Tailing Mix was then added and samples
were incubated at 37
◦
C for 30min. These samples were incubated
with RNA Index Adapter and Ligation Mix at 30
◦
C for 10min.
The end-repaired DNA was purified using Ampure XP Beads
(AGENCOURT). Several rounds of PCR amplification with a
PCR Primer Cocktail and PCR Master Mix were performed to
enrich the cDNA fragments. The PCR products were finally
purified with Ampure XP Beads (AGENCOURT).
After the libraries were obtained, they were amplified on cBot
to generate a cluster on the flowcell (TruSeq PE Cluster Kit
V3–cBot–HS, Illumina). The amplified flowcell was sequenced
using the HiSeq 2000 System (TruSeq SBS KIT-HS V3, Illumina)
with a read length of 100 bp, producing on average 24M paired-
end sequence reads per sample. Sequencing reads were aligned
to the mouse genome build mm10/GRCm38 with the HISAT2
aligner (17). The number of reads uniquely aligned (mapping
quality score q > 10) to the exonic region of each gene were
counted using HTSeq (18), based on GENCODE version 9
mouse gene annotation. Only genes that achieved at least one
count per million (CPM) mapped reads in at least one sample
were included, leading to 15,687 filtered genes in total. Read
counts were further normalized using the conditional quantile
normalization (cqn) method (19), accounting for gene length
and GC content, with the FPKM (Fragments Per Kilobase of
transcript per Million mapped fragments) values derived for
genes across the eight samples. The overall gene expression
correlations between samples were subsequently calculated. The
data of transcriptome sequencing has been uploaded to GEO, the
series entry number is GSE151813. The genes expressed at higher
levels in KP-LC compared to WT-iPSCs or KP-LC compared to
KPL 160424S were analyzed. Tumor-associated antigens such as
CTA, CEA were searched among them. Meanwhile, GO analysis
was applied to determine highly expressed genes in KP-LC using
the https://david.ncifcrf.gov/summary.jsp~website.
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Cytotoxicity Assay
Cells were seeded at 4 × 103 to 6 × 103 cells per well in 96-
well plates and infected with Ad5/ VVL15-RFP 14–18 h later at
starting multiplicity of infection (MOI) of 1,000 PFU/cell. Cells
were incubated at 37◦C, 5% CO2 incubator for 6 days after
viral infection. Cell survival was detected by SpectraMax M5e
microplate reader.
Viral Replication Assay
Cells were seeded at 2 × 105 cells per well in 24-well plates.
Fourteen to eighteen hours later, cells from three wells were
harvested with trypsin and cell number per well-determined.
Cells were infected with Ad5 (MOI:10 PFU/cell) for 4 h or
VVL15-RFP (MOI: 1 PFU/cell) for 2 h. Twenty-four wells were
then switched to DMEM + 10% FBS. The other 24 wells were
switched to DMEM+ 10% FBS+ 200µg/ml MMC for 2.5 h, and
then DMEM+ 10% FBS. Cells were collected in triplicate at 24-h
intervals up to 96 h after infection, freeze-thawed three times and
titrated on JH293 cells for Ad5 or CV1 cells for VVL15-RFP. The
Reed-Muench mathematical method was used to calculate the
50% tissue culture infective dose (TCID50) value for each sample
(20). Viral burst titers were converted to PFU per cell based on
the number of cells present at viral infection.
Cell Proliferation and Plate Colony
Formation of KP-LC With Ad5/VVL15-RFP
Infection and MMC Treatment
Cells were seeded at 3,000 cells per well in 96-well plates.
Fourteen to eighteen hours later, cells were infected with Ad5
(MOI: 50 PFU/cell) for 4 h/VVL15-RFP (MOI: 1 PFU/cell) for
2 h. Then the medium was switched to DMEM + 10% FBS +
200µg/ml MMC for 2.5 h, and then DMEM + 10% FBS. Cell
survival 24 or 72 h after MMC treatment was determined byMTS
assay by SpectraMax M5e microplate reader.
In six-well plates, 2.5 × 105 cells per well were seeded. After
14–18 h, cells in 3 wells were digested with trypsin and the
average number of cells in each well was calculated. Cells in
the remaining wells were infected with Ad5 (MOI: 50 PFU/cell)
for 4 h or VVL15-RFP (MOI: 1 PFU/cell) for 2 h. After that,
the medium was changed to DMEM + 10% FBS + 200µg/ml
MMC and incubated for 2.5 h, and then themediumwas changed
to DMEM + 10% FBS. Forty-eight and ninety-six hours after
MMC treatment, cells were digested with trypsin and the average
number of cells per well was calculated. After counting, the cells
were seeded in new six-well plates for plate colony formation
experiments. Meanwhile, KP-LC without virus infection and
MMC treatment was seeded into six-well plates at 300 or 600 cells
per well as a normal control. Six days later, cells of the normal
control group grew into visible colonies. The six-well plates were
fixed with 4% paraformaldehyde at room temperature for 15min,
and washed twice with PBS. The wells were stained with crystal
violet for 20min, rinsed with tap water and photographed.
Cell Growth Curve
6 × 104 cells/well were cultured in 96-well plates for 5 days in
DMEM + 10% FBS. Cell counts were carried out using Incucyte
every 2 h.
Soft Agar Colony Formation Assay
Two percent agar and DMEM + FBS were mixed to a final
concentration of 0.5% agar and 20% FBS, and the mixture
placed in to 24-well plates as a base layer. Cells were trypsinized
and suspended in DMEM + 20% FBS. 0.5% agar and cells
suspension were mixed to a final concentration of 0.2% agar
and added over the solid base layer. DMEM + 10% FBS was
added after top layer was solidified. Plates were incubated at
37
◦
C for 2 weeks. Colonies of each well were visualized using
an Olympus IX51 microscope, counted and colony forming
efficiency (total number of colonies/initial number of cells)
was calculated.
Plate Formation Assay
50/100/200 cells/well were seeded in 96-well plates in DMEM
+ 10% FBS. The plates were then put into Incucyte to
take pictures. Two weeks later, colonies of each well were
counted, averaged and colony forming efficiency calculated
as above.
Wound Healing Assay
3 × 104 cells/well were cultured in 96-well plates for 1 day.
Plates were then scratched with the 96 well pin block and put
into Incucyte. Pictures were taken every 2 h and relative wound
density was calculated.
Western Blot
Cells were seeded at 1 × 106 cells per well in six-well plates.
Fourteen to eighteen hours later the cell number per well was
determined. Cells were infected with Ad5 (MOI: 50 PFU/cell)
for 4 h/VVL15-RFP (MOI: 1 PFU/cell) for 2 h. The medium
was switched to DMEM + 10% FBS + 200µg/ml MMC for
2.5 h, and then DMEM + 10% FBS. Cells were collected at
24 and 72 h after MMC treatment. Cells were lysed by RIPA
lysis buffer + PMSF (Solarbio, R0020), and concentration of
protein was detected by BCA kit (Solarbio, PC0020). Protein
was separated by SDS-PAGE gel (CWBIO, CW0022S), and
transferred to a piece of PVDF membrane (BEIJING DINGGUO
CHANGSHENG BIOTECHNOLOGY CO., XLL094-2). The
membrane was blocked with 10% skimmilk for 1 h and incubated
with the primary antibodies at 4◦C overnight diluted in 5%
skim milk.
Following incubation, the membrane was rinsed with TBST
3 times and incubated with secondary antibodies diluted in 5%
skim milk at room temperature for 1 h. The membrane was
rinsed 3 times with TBST and ECL added (Thermo Scientific,
NC15079) prior to exposure (GE Amersham Imager 600).
Dilutions and catalog numbers for primary antibodies were
as follows: Adenovirus Type 5 E1A Ab-1, Mouse Monoclonal
Antibody (1:300 dilution) (Thermo, MS-587-P1), Vaccinia virus
(Polyclonal Antibody) (1:300 dilution) (AbD Serotec, 9503-
2057), GAPDHAntibody (MouseMonoclonal) (1:5,000 dilution)
(Proteintech, 60004-1-Ig). The secondary antibody: Peroxidase-
Conjugated Goat anti-Mouse IgG (1:5,000 dilution) (ZSGB-BIO,
ZB-2305), Peroxidase-Conjugated Goat anti-Rabbit IgG (1:5,000
dilution) (ZSGB-BIO, ZB-2301).
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In vivo Experiments
All animal procedures were approved by the Animal Welfare
and Research Ethics Committee of Zhengzhou University
(Zhengzhou, China). Mice were housed in groups in accordance
with the regulations for mouse welfare and ethics of Zhengzhou
University with 12 h dark-light cycles and free access to food
and water.
LSL-KRASG12D/+; LSL-Trp53R172H/+ (KP) mice were kindly
provided by David Tuveson. Genotyping was performed using
the following primers; KRAS F: 5′-CCATGGCTTGAGTAAG
TCTGC-3′ KRAS R 5′-CGCAGACTGTAGAGCAGCG-3′ (550
bp); P53_F: 5′-AGCTAGCCACCATGGCTTGAGTAAGTCTG
CA-3′ P53_R: 5′-CTTGGAGACATAGCCACACTG-3′ (270 bp).
This model is modified heterozygous KRASG12D and Trp53R172H
on 129 mouse background. These two point mutations were
silenced by a loxp-stop-loxp (LSL) cassette in the absence of
Cre. 2.5 × 107 PFU Ad-Cre was delivered to 10–12 week (20–
28 g) male mice intranasally. After the intranasal inhalation
of Ad-Cre, the two mutations were activated and lung cancer
developed gradually. To acquire lung cancer cell lines from
this model, lungs of KP mice that had been infected with Ad-
Cre were surgically dissected at 8 and 16 weeks, and rinsed
in PBS twice. Lungs were dissected in a small amount of PBS
+ 10% BSA and the cells cultured in ACL-4 media (RPMI
1640 with 20µg/ml insulin, 10µg/ml transferrin, 25 nM sodium
selenite, 50 nM hydrocortisone, 1 ng/ml epidermal growth
factor, 10µM ethanolamine, 10µM phosphorylethanolamine,
100 pM triiodothyronine, 2 mg/ml bovine serum albumin,
0.5mMHEPES, 0.5mM sodium pyruvate and 2mM glutamine).
After 2 passages, ACL-4 media was switched to DMEM +
10% FBS.
Male C57/BL6 mice and nude mice were purchased from
Vitalriver.com, Beijing, China.
In subcutaneous tumor models, 4 to 5-weeks old, 16–18 g
male mice were randomly assigned to treatment groups and
tumor growth was measured using electronic calipers [tumor
volume = (length × width2 × π)/6] until tumor volume
reached 2,500 mm3 or ulcerated, at which point the animal
was sacrificed. For KP lung cancer models, animals were
assigned randomly to treatment groups and animal survival
was monitored by assessment of animal well-being every other
day. In the survival experiments, the animal was sacrificed
when one of the following situations occurred: animal was
curled up motionlessly, hair became fluffy and messy, animal
showed no response to external stimuli, weight loss exceeding
2 g in 2 days. Lung tissue was collected from each mouse to
confirm, using H&E staining, that all mice developed lung
cancer. Animal caretakers were blinded to treatment groups in
all cases.
Statistical analysis was carried out using Graph Pad Prism
5 and SPSS 19.0 software. The results were represented as
mean ± standard or deviation (SD) or ± standard error of the
mean (SEM). Differences between groups were analyzed using
Students’ unpaired T-tests or Kaplan–Meier survival analysis.
Differences were considered statistically significant when the
p < 0.05.
VIReST Vaccinations for Subcutaneous
Tumor Experiments
KP-LC cells were infected with Ad5 at an MOI of 50 PFU/cell
in serum-free DMEM for 4 h. Following infection, medium was
switched to DMEM + 10% FBS + 200µg/ml mitomycin C
(MMC) (Meilun Biotechnology, 50-07-7) and cells incubated at
37◦C for 2.5 h. Cells were washed with PBS twice, harvested
with trypsin and diluted with PBS to 2 × 106 cells/100
µl. Ad5-infected cells were injected subcutaneously (s.c) as a
prime vaccination using 100 µl per inoculation in the right
flank of male KP littermates. KP-LC cells were infected with
VVL15 at an MOI of 1 PFU/cell for 2 h and then MMC-
treated as for AdV-infected cells. Four weeks after prime
vaccination, cells treated with VVL15-MMC were injected s.c in
the same side as a booster vaccination. Two weeks after boost,
KPL160302S/KPL 160424S cells were injected s.c in 100 µl (2 ×
106 cells) per inoculation, in the right flank and tumor growth
was monitored.
Immunohistochemistry
The tissues were collected at different time points, dipped
in isopentane and frozen at −80◦C. Tissues were cut into
6µm sections by freezing microtome (Leica, CM1950). The
sections were fixed with −20
◦
C acetone for 10min, washed
three times with PBS. Then the slides were incubated with 3%
H2O2 for 8min, washed twice with PBS and slides blocked
with 10% goat serum for 30min. Slides were incubated with
the primary antibodies at 4
◦
C overnight diluted in PBS.
Following incubation, the slides were rinsed 3 times with
PBS. Polink-2 plus polymer HRP detection system for rat
primary antibody (ZSGB-BIO, PV-9004) and DAB kit (ZSGB-
BIO, ZLI-9018) were used. The slides were flushed using
tap water thoroughly, dyed by hematoxylin, flushed by tap
water, differentiated by hydrochloric acid alcohol, dehydrated,
and sealed. The images were visualized using an Olympus
BX41 microscope. Dilutions and catalog numbers for primary
antibodies were as follows: CD4 antibody (1:100 dilution)
(BioLegend, 100402), CD8 antibody (1:100 dilution) (BioLegend,
100702).
Ten high-power fields (HPF) were randomly selected from
each group to count lymphocytes, three mice per group at
each time point. Statistical graphs show the mean ± standard
error of the mean (SEM) of each group and compared using
independent T-test.
Establishment of Orthotopic Lung Cancer
Model
Ad-Cre was intranasally delivered to KRASLSL−G12D/+;
p53LSL−R172H/+ (KP) mice between 10 and 12 weeks of age.
DMEM + Ad5-Cre + 10mM CaCl2 were incubated at room
temperature for 20min to form calcium phosphate precipitates.
Meanwhile, mice were anesthetized using avertin at 0.45 mg/g
body weight for males via intra-peritoneal injection. A total
volume of 75 µl containing 2.5 × 107 PFU per mouse was
delivered as previously described (21).
Frontiers in Immunology | www.frontiersin.org 6 August 2020 | Volume 11 | Article 1996
Zhang et al. Stem Cell-Based Lung Cancer Vaccination
Vaccinations for Survival Experiments
Ad5-infected KP-LC, KPL 160302S, or KPL 160424S cells
produced as described above were injected s.c, using 100 µl per
inoculation, in the right flank of male KP mice 2 weeks 4 days
after Ad-Cre inhalation, as a prime. Four weeks later, cells treated
with VVL15-MMC were injected subcutaneously in the same
side as a boost. For analysis of α-PD1 combination, 600 µg α-
PD1 (Bioxcell) was administered to mice intra-peritoneally (i.p.)
2 weeks post-prime and 1 and 3 weeks post-booster injection.
Flow Cytometric Analysis
Splenocytes of three mice vaccinated by KP-LC and 3 mice
vaccinated by PBS were stained with CD3e (FITC) (eBioscience,
11-0031-86), CD4 (APC) (eBioscience, 17-0041-82), CD8a (PE)
(eBioscience, 12-0081-85), CD44 (eFluor 450) (eBioscience, 48-
0441-80), CD62L (PerCP-Cyanine5.5) (eBioscience, 4300748) for
30min at 4◦C. After washing, stained cells were analyzed on an
ACEA NovoCyte flow cytometer.
IFNγ Expression Induced by Vaccination
Spleens of three mice vaccinated using KP-LC and three mice
vaccinated using PBS 3 weeks after boost were harvested under
sterile conditions. Spleens were mashed through 70µm cell
strainers (BIOFIL, CSS010070), centrifuged at and re-suspended
in 5ml of RBC lysis buffer, washed with PBS, centrifuged and re-
suspended with T cell media (TCM) (RPMI-1640 + 10% FBS
+ 1% streptomycin/ penicillin + 1% sodium pyruvate + 1%
non-essential amino acids) to a final concentration of 5 × 106
cells/ml.
KP-LC, KPL 160302S, KPL160424S, KPL-234S, and MOSEC
as stimulator cells were incubated with TCM+ 0.2 mg/ml MMC
for 2.5 h. The cells were washed twice with PBS, trypsinized and
re-suspended in TCM to a final concentration of 5× 105 cells/ml.
Peptides of K-RAS (GADGVGKSA) (GL Biochem, 492748),
B8R (TSYKFESV) (GL Biochem, 492745), OVA(SIINFEKL) (GL
Biochem, 492746) were diluted in TCM to 100 µg/ml.
One hundredmicroliters of each of the splenocyte suspensions
were co-cultured with 100 µl of stimulator cell suspension or
peptide in a round bottomed 96 well plate. Background contained
5× 105 splenocytes in 200 µl TCM. The plates were incubated at
37
◦
C, 5% CO2 for 3 days. The plates were centrifuged at 512 g for
5min. The concentration of IFNγ in supernatants was measured
using mouse IFNγ ELISA Ready-SET-Go kit (eBioscience, 88-
7314-88).
In vivo CD8+ or CD4+ T Cell Depletion
α-CD8 (TIB2100) or α-CD4 (GK1.5) (Provided by Professor
Shengdian Wang, the Chinese Academy of Sciences, Institute of
Biophysics) was injected into the abdominal cavity of the KPmice
1 day before prime and two times/week in the interval between
prime and boost, and 4 weeks after boost at 200 µg/mouse/time
point. CD8+ or CD4+ T cell depletion was confirmed using flow
cytometric analysis throughout the experiment.
Mouse Anti-nuclear Antibody ELISA
Three mice vaccinated using KP-LC and three mice vaccinated
using PBS had blood collected from tail tips 3 weeks after boost.
The blood was coagulated at 37◦C for 15min and centrifuged
20min at 845 g. Supernatant was serum, and the concentration of
anti-nuclear antibody in serum was measured using mouse anti-
nuclear antibody kit (Nanjing Senbeijia Biological Technology
Co., SBJ-MO134-96T).
Statistical Analysis
GraphPad Prism 6 was used for comparative statistical analysis.
Dual condition comparisons were made using the unpaired
student T-test. For more than one condition or for an additional
variable such as time, one or two-way ANOVAs, respectively
were performed, with post-hoc Tukey tests to compare treatment
pairs. Survival data was represented by Kaplan-Meier plots with
log rank analyses to delineate whether any differences between
specific treatment pairs were statistically significant. ∗p < 0.05,
∗∗p < 0.01, and ∗∗∗p < 0.001.
RESULTS
Lineage Differentiation and Transformation
of iPSCs Provides an Antigenically
Compatible Whole Cell Lung Cancer
Vaccine
We have previously generated a wide type iPS cell line from
129J/C57/BL6 male mice and modified the genome with Cre-
dependent LSL-KRASG12D/+; LSL-Trp53R172H/+, to create
WT-KP iPSCs. The introduction of driver mutations prior to
lineage differentiation had no impact on the pluripotency of
iPSCs as demonstrated by the ability to form characteristic
teratoma when inoculated into nude mice (Figure 1A). WT-
KP iPSCs were directed to differentiation to lung progenitor
cells following the protocol shown in Figure 1B. To confirm
effective induction, markers of iPSC, endoderm, anterior foregut
endoderm (AFE), and lung progenitors (LP) were detected by
immunofluorescence (Figure 1C) and RT-qPCR (Figure S1A).
iPSC-derived LP cells were then infected with non-replicating
Ad5 vector expressing Cre (AdCre) to induce mutant KRASG12D
and p53R172H expression and transformation to lung cancer cells
(KP-LC) (Figure 1D). Genotyping confirmed the presence of
mutant KRAS in the KP-LC cell line and KPL 160302S and
KPL160424S cell lines [lung adenocarcinoma cell lines derived
from the lung cancer KP transgenic mouse model (21)], but
not in LP cells that were not infected with AdCre. Similarly,
mutant p53 was detected in KP-LC cell line but not in the AdCre
uninfected lung progenitor (LP) cells that do not express mutated
p53 (Figure S1B). Furthermore, KP-LC and KPL 160302S, KPL
160424S all had abnormal chromosome profiles (Figure S1C).
These three lung cancer cell lines had similar growth rate in vitro
(Figure S1D). Investigations into the tumorigenicity of iPSC-
derived KP-LC cells demonstrated these cells were able to develop
into subcutaneous tumors when inoculated into the flank of
KP transgenic littermate mice or C57/BL6 mice that had no
pre-disposition to cancer (Figure 1E and Figure S1E), forming
tumors pathologically similar to those formed after inoculation
of KPL 160302S and KPL 160424S tumor cells derived from
the induced KP transgenic lung cancer model (Figure 1E and
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FIGURE 1 | Antigenically relevant lung cancer cells can be derived from
murine iPSCs. (A) H&E staining of tissues derived after LSL-KRASG12D/+;
LSL-Trp53R172H/+ iPSCs were subcutaneously injected into nude mice to form
teratoma. (B) Schematic of the protocol employed for stepwise differentiation
of LSL-KRASG12D/+; LSL-Trp53R172H/+ iPSCs to lung cancer cells. (C)
Immunofluorescence images to examine expression of markers indicative of
stages of induction of lung progenitor cells from iPSC. DAPI was used to stain
for nuclear content. (D) Morphology of WT-KP iPSCs, embryoid bodies,
anterior foregut endoderm, lung progenitors, and KP-LC. On the 10th day of
lung progenitors, cells displayed structures akin to lung buds. Tubular
structures could be observed at the 4th generation after infection of Ad5-Cre.
Without the infection of Ad5-Cre, lung progenitors gradually became
senescent. After serial passage post-infection of Ad5-Cre, cells transformed to
lung cancer cells. (E) Subcutaneous tumor growth curve of KP littermates
bearing KP-LC, KPL 160302S, and KPL 160424S tumors with the initial dose
of 2 × 106 cells/ mouse. Mean ± SEM is shown. N = 7/group. H&E staining of
subcutaneous tumors at day 21 is shown beneath the growth curve. (F)
Indicated cell lines were subjected to RNA deep sequencing and a
transcriptome expression correlation matrix, based on 15,687 filtered genes,
was generated.
Figure S1E). Scratch assays to examine in vitro invasion of cells
demonstrated that over 90% of the wound of KPL 160424S
cells, from an advanced lung cancer model, healed 16 h after
scratch. At the same time point, the wound in KPL 160302S cells,
which came from an early stage lung cancer model, demonstrated
healing at <20% and KP-LC cells showed a 40% heal from
scratch (Figure S1F). Both KP-LC and KPL 160302S were able
to form colonies in the soft agar (Figure S1G) and plate colony
formation assay (Figure S1H). Most importantly, analysis of the
transcriptome of KP-LC cells demonstrated a high similarity
between KP-LC cells derived from iPSCs and the cell lines derived
from the transgenic mouse model (KPL 160302S and KPL
160424S) (Figure 1F). KP-LC cells had the highest similarity with
KPL 160302S which came from the early stage lung cancer model
(91%), followed by KPL 160424S which came from the advanced
lung cancer model (84%). We speculate that KP-LC derived
from iPSC retained more neoantigens/tumor-associated antigens
similar to cells from early staged lung cancer model because it
had not been screened by the immune system. Similarity between
KP-LC and untransformed iPSCs (WT iPSC derived from KPC
transgenic mice with wild-type KRAS and p53 or WT-KP iPSCs
derived from littermate mice with stable insertion of KRASG12D
and p53R172H) was lower, demonstrating the limitations of
vaccination strategies based on the use of unmodified iPSCs
as previously reported (22). Cancer associated genes such as
MageE1, Morc2b, Morc4, Cage1, Brdt, IL13ra1, were expressed at
significantly higher levels in KP-LC thanWT-iPSCs (Figure S2A)
and these genes were enriched in several pathways associated
with cancer, including the PI3K-Akt signaling pathway, cancer
proteoglycans, the Ras signaling pathway, cancer associated
MicroRNAs, the Rap1 signaling pathway, HTLV-1 infection,
the MAPK signaling pathway and ECM-receptor interactions
(Figure S2C). Furthermore, when compared to KPC or KP-AC
iPSCs, which were derived in the same way, using the same
driver mutations, but induced to pancreatic lineage tumor cells,
and TB11381 cells derived from the transgenic pancreatic cancer
model with the same driver mutations, concordance was low.
This demonstrates that the lineage specific genetic and epigenetic
profiles and not the driver mutation per se drive the accumulation
of neo-antigens or/and tumor-associated antigens (Figure 1F).
Oncolytic Viruses Can Successfully Infect
and Express Viral Proteins in KP-LC Cells
Lack of immunogenicity plays a central role in therapeutic tumor
vaccine failure, thus provision of an effective adjuvant is critical
for inducing robust anti-tumor immune activity, even within
the pre-malignant environment. Virus-infected cell vaccines,
whereby tumor cells are pre-infected with replicating tumor
tropic virus prior to delivery as a vaccine, has previously been
shown to induce strong anti-tumor immune reactions (23),
and we have demonstrated that replicating oncolytic Vaccinia
virus (VV) and Adenovirus (AdV) can induce the necessary
danger signals and inflammatory environment required for anti-
tumor immune induction (10). To validate their use in a lung
cancer vaccination regime, we investigated the ability of VV
and AdV to replicate in and kill iPSC-derived KP-LC cells in
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vitro. Both viruses were significantly more cytotoxic in KP-LC
cells compared to KPL160302S cells derived from the induced
transgenic mouse model (Figure 2A). Consistent with previous
reports (15), Ad5 replicated poorly in murine cells, including
KP-LC (Figure 2B), but viral protein expression was detected
after infection (Figure 2F). VV replicated and expressed viral
protein efficiently in KP-LC cells (Figures 2B,F). In order to
ensure safety of the vaccination protocol, we completely inhibited
ongoing cell proliferation and virus replication using mitomycin-
C (MMC) (Figures 2B–E). This had the effect of preventing
both cell proliferation and viral replication, but viral protein
expression, required for adequate stimulation of anti-tumor
immune responses, persisted for at least 72 h post-infection
(Figure 2F).
A VIReST Regime Using OV-Infected
iPSC-Derived KP-LC Cells Prevents Tumor
Growth in Immunocompetent Mice
To demonstrate the principle of prophylactic vaccination, the
efficacy of a Virus Infected, Reprogrammed Somatic cell-derived
Tumor cell (VIReST) vaccination regime was examined using
subcutaneous models of lung cancer in immunocompetent
mice. As detailed in Figure 3A, KP littermates that are not
disposed to cancer development were immunized at day 0
using AdV-infected, MMC-treated KP-LC cells. Four weeks
after prime vaccination, VV-infected, MMC-treated KP-LC cells
were injected subcutaneously as a boost. Two weeks following
this booster vaccination, lung cancer cell lines KPL 160302S
(Figure 3B) or KPL 160424S (Figure 3F) were inoculated into
the flank of immunized mice to form subcutaneous tumor and
tumor growth measured. While prophylaxis did not completely
prevent the growth of tumors after challenge, it was able to
delay and impair growth after challenge with a large number
of tumor cells compared to PBS vaccination. To determine
the mechanisms responsible for efficacy, tumors were analyzed
using immunohistochemistry (IHC) at day 24 (KPL 160302S)
or 31 (KPL 160424S) after re-challenge. The numbers of
CD8+ and CD4+ T cells infiltrating the tumors were analyzed
(Figures 3C–E,G–I). In both models, prophylactic vaccination
using the KP-LC VIReST regime resulted in a heavier infiltration
of both CD8+ and CD4+ T cells, demonstrating that vaccination
can induce adaptive immune responses capable of homing to the
site of tumor development to impede growth.
VIReST Using iPSC-Derived Lung Cancer
Cells Evokes Anti-tumor Immune
Responses in an Induced Transgenic
Model of Lung Cancer
We next investigated the KP-LC-based VIReST regime in a
more pathologically relevant model of lung cancer using the
lung cancer transgenic mouse model previously described (21).
KRASLSL−G12D/+; Trp53LSL−R172H/+ mice were intra-nasally
(i.n.) infected with Ad-Cre to induce KRASG12D and P53R172H
expression within the lung and drive carcinogenesis. H&E
staining of lung sections carried out 3–28 weeks after AdCre
delivery demonstrated that early lesions could not be detected
3 weeks post-infection (Figure S3) suggesting that disease had
not yet developed in these animals or was at an early stage,
undetectable by histopathology examination. After 8 weeks,
tumors with enlarged nuclei with prominent nucleoli were
observed. In contrast, KP mice that were not infected with
AdCre did not develop signs of lung carcinogenesis at any
age (Figure S3). Based on the observed progression, mice were
treated 2 weeks and 4 days post-AdCre infection with a prime-
boost VIReST regime as shown in Figure 4A.
One, two, and three weeks following booster injection, CD4+
and CD8+ T cell infiltration into the lungs was observed
(Figures 4B–D). CD8+ T cell infiltration into lung tissues was
significantly enhanced by VIReST treatment at each timepoint.
CD4+ T cell infiltration was also significantly enhanced by
treatment, but this advantage was lost 3 weeks post-booster
vaccination, although it should be noted that both anti-tumor
CD4+ populations and TReg inhibitory CD4+ populations will
be detected using this method. Of note, the immune response
caused by KP-LC vaccination was similar to that induced by
KPL 160302S vaccination using the same regime for they both
elicited more CD8+ T cells infiltration 1–3 weeks post-booster
vaccination and more CD4+ T cells infiltration 1–2 weeks
post-booster vaccination. To further investigate the breadth of
anti-tumor immunity, splenocytes from immunized mice were
gathered 3 weeks post-boost and the T cell effector phenotype
(Figures 4E,F) and ex vivo responses to several lung cancer cell
lines and specific antigens were determined (Figure 4G). KP-
LC VIReST induced more effector CD8+ T cell populations
compared to PBS vaccination (Figures 4E,F). In addition, KP-LC
VIReST resulted in significantly enhanced IFNγ responses to all
lung cancer cell lines and the KRAS epitope (Figure 4G). Of note,
IFNγ responses induced by KPL 160424S cells, which was derived
from the advanced lung cancer model and had the same driver
mutations as KP-LC, was significantly lower compared to other
lung cancer cell lines stimulation. KP-LC VIReST also resulted
in significantly enhanced IFNγ responses to a mouse ovarian
surface epithelial cell line (MOSEC). However, the production
of IFNγ induced by MOSEC is significantly lower than KP-LC
(Figure 4G). This phenomenonmay be caused by some antigenic
similarity between MOSEC and mouse lung cancer cell lines
and warrants further investigation into shared antigens. Together
these results demonstrate the ability of KP-LC VIReST to induce
potent anti-tumor immune reactions within the emerging tumor
microenvironment (TME) in a physiologically relevant model of
lung cancer.
VIReST Can Delay Tumor Development in
an Induced Transgenic Lung Cancer Model
in a CD8+ and CD4+ T Cell Dependent
Manner
To determine treatment efficacy, animals were immunized
following the regime shown in Figure 4A and the progression
and survival was monitored. The lung tissues of mice were
collected 10.5 and 15.5 weeks after Ad-Cre infection. The tumors
of the KP-LC VIReST group were significantly smaller than
PBS group (Figures 5A,B). KP-LC VIReST was able to delay
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FIGURE 2 | AdV and VV can infect and replicate in transformed iPSCs and mitomycin-C treatment inhibits ongoing replication and tumor cell proliferation. (A)
Cytotoxicity of Ad5 or VV on iPSC-derived KP-LC cells and KPL 160302S lung tumor cells. Cell death was determined by MTS assay 144 h post-infection. Mean
EC50 values ± SEM are shown. (B) Production of infectious Ad5 or VV virions in KP-LC cells. Cells were infected with virus and were untreated or treated with
mitomycin C. Mean viral replication ± SEM was determined at 24 h intervals for 96 h by TCID50 assay. JH293 cells for Ad5 or CV1 cells for VVL15-RFP. (C) Cell
proliferation of KP-LC cells after infection and mitomycin-C treatment was determined using MTS assay at 24 and 72 h post-mitomycin C treatment. Mean OD490nm
values ± SEM are shown. n = 3/group. (D) Cell proliferation of KP-LC cells after infection and mitomycin-C treatment was determined by cell counting at 48 and 96 h
post-mitomycin C treatment. n = 3/group. (E) Plate colony formation of KP-LC cells after infection and mitomycin-C treatment. (F) Viral protein expression was
determined in KP-LC or KPL 160302S cells at 24 and 72 h post-infection +/– mitomycin C treatment of cells. Anti-E1A was used to confirm AdV protein expression.
Anti-VV coat protein was used to confirm VV protein expression. GAPDH was used as a loading control. **p < 0.01 and ***p < 0.001.
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FIGURE 3 | A KP-LC VIReST immunization regime can protect against tumor
growth in a subcutaneous lung cancer model. (A) KP littermates were
immunized with AdV-infected KP-LC cells, followed by a booster immunization
using VV-infected KP-LC cells 4 weeks later. Two weeks after boost, mice
were challenged using 2 × 106 KPL 160302S or KPL 160424S cells. (B) Mice
were treated using the regime shown in (A) and KPL 160302S tumor growth
monitored. Mean subcutaneous tumor sizes ± SEM are shown for each group
and compared using a 2-way ANOVA with Bonferroni post-hoc testing (n =
7/group). (C) Representative images of immuno-histochemical staining for
CD8+ and CD4+ T cells in subcutaneous tumors derived from (B) 24 days
post-inoculation. (D,E) Lymphocytes were counted in 10 high power fields
(HPFs) randomly selected from each group. Mean ± SEM are shown for each
group of CD8+ T cells (D) or CD4+ T cells (E) and compared using an
independent T-test. (F) KP littermates (K+/+, PLSL−R172H/+) immunized as in
(A) were re-challenged using KPL 160424S tumor cells (n = 7/group). Mean
subcutaneous tumor sizes ± SEM are shown for each group and compared
using a 2-way ANOVA with Bonferroni post-hoc testing. (G) Representative
images of immuno-histochemical staining for CD8+ and CD4+ T cells in
subcutaneous tumors derived from (F) 31 days post-inoculation. (H,I)
Lymphocytes were counted in 10 HPFs randomly selected from each group of
CD8+ T cells (H) or CD4+ T cells (I). Mean ± SEM are shown for each group
and compared using an independent T-test. *p < 0.05, **p < 0.01, and
***p < 0.001.
disease onset and mortality in this model compared to treatment
with PBS, increasing median survival time by 17% (Figure 5C
and Figure S4). Furthermore, KPL 160302S vaccination also
protected this model, increasing median survival time by 21%,
but vaccination using KPL 160424S cells did not have a protective
function (Figure 5C and Figure S4). This difference may be
attributed to the fact that KP-LC and KPL 160302S had a
higher similarity at the transcriptome level (Figure 1F) and
elicited similar immune responses (Figures 4B–D). MageE1, a
cancer-testis antigen (CTA), was expressed at significantly higher
levels in KP-LC compared to KPL 160424S (Figure S2B) and
as previously, genes differentially expressed by KP-LC and KPL
160424S were enriched in several pathways associated with
cancer (Figure S2D). This may form part of the reason why
the efficacy of KP-LC is higher than KPL 160424S. Depletion of
both CD8+ (Figure 5D) and CD4+ (Figure 5E) T cells reduced
the survival advantage afforded by KP-LC VIReST treatment
(Figure S5), demonstrating that the induction of adaptive
immune responses is vital for treatment efficacy. Given the
sensitivity of some lung tumors to immune checkpoint inhibition
(ICI), coupled with an impressive induction of adaptive T
cell immunity after vaccination, we reasoned that combination
treatment of VIReST with ICI may improve overall mortality.
Interestingly however, when induced transgenic mice were
treated with α-PD1 antibody, no synergy with VIReST treatment
was observed and the efficacy was not enhanced (Figure 5F and
Figure S5), although the PD1 blockade did improve the survival
of animals compared to untreated control animals. This suggests
that treatment failure in this model may not be due to PD1-
PDL1-mediated T cell anergy and alternative immunotherapeutic
approaches may be considered as synergistic partners.
Of note, an important concern in the development of vaccines
derived from ‘‘self’’-somatic cells is the possibility of breaking
immune tolerance against self-antigens. However, none of the
immunized mice developed any evident signs of autoimmune
disorders and there was no difference in the amount of circulating
anti-nuclear antibodies (ANA) detected between immunized and
unimmunized mice (Figure 5G), suggesting that the VIReST
regimen was not associated with significant risk of induction of
autoimmunity. In addition, no tumor formation was detected
at the site of inoculation, demonstrating VIReST as a safe
approach for prophylactic prevention of lung cancer as depicted
in Figure 6.
DISCUSSION
Vaccination strategies for lung cancer have historically been
unsuccessful, with no positive reports through large, late stage
clinical trials over the last decade. However, our improved
understanding of the fundamental processes underlying the
cancer-immunity cycle has led to a resurgence of interest
in developing cancer vaccination strategies, which will be
underpinned by rational approaches to selection of tumor
antigen targets and prevention of immune suppression. We have
recently described a novel vaccination strategy for pancreatic
cancer that overcomes current limitations of antigen selection by
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FIGURE 4 | A VIReST regime using induced KP-LC tumor cells induces potent anti-tumor immune responses. (A) Schematic representing the immunization protocol.
LSL-KRASG12D/+; LSL-Trp53R172H/+ mice were infected with Ad-Cre to induce lung cancer development. Two weeks 4 days later, mice were immunized with
AdV-infected, mitomycin C-treated KP-LC iPSC-derived tumor cells, KPL 160302S, lung tumor cells, or KPL 160424S lung tumor cells. Four weeks later, a booster of
VV-infected, mitomycin C-treated KP-LC, KPL 160302S, KPL 160424S cells were subcutaneously given. Control animals were treated with PBS at the same time
points. (B) Representative images of immunohistochemical staining for CD8+ or CD4+ T cells in lung tissues from immunized cre-infected KP mice 1, 2, and 3 weeks
post-boost. (C,D) Lymphocytes were counted in 10 high power fields (HPFs) randomly selected from each group of CD8+ T cells (C) or CD4+ T cells (D). Three mice
per time point per group were used. Mean ± SEM are shown for each group and compared using a one-way ANOVA with Tukey post-test. (E) Spleens of KP-LC
immunized mice were collected 3 weeks post-boost and stained for CD3, CD8, CD4, CD44, and CD62L. Representative images of flow cytometry were shown. (F)
The percentages of effector memory T cells (TEM) (CD44hi; CD62Llo) of (E) are shown (n = 3/group). Mean ± SEM are shown for each group and compared using an
independent t-test. (G) Three weeks post-booster vaccination, splenocytes were re-stimulated ex-vivo with growth-arrested lung cancer cells as shown, or mouse
ovarian surface epithelial cells (MOSEC) or K-RAS or B8R or OVA peptides or media and IFNγ production measured using ELISA. Three mice per group were analyzed
in triplicate and the mean IFNγ production ± SEM is shown. Significance was analyzed using an independent T-test. *p < 0.05, **p < 0.01, and ***p < 0.001.
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FIGURE 5 | A VIReST regime using iPSC-derived lung tumor cells delays
mortality in an induced transgenic model of lung cancer. Ten to twelve
week-old KP transgenic mice were immunized using a VIReST regime as
shown in Figure 4A. (A) Lung tissues of mice 10.5 or 15.5 weeks
post-Ad-Cre infection were collected. Representative images of H&E staining
are shown. Tumor tissue is indicated by the arrows. (B) Tumors present in the
H&E stained sections were counted. Significance was analyzed using a
student’s independent T-test. (C) After treatment with PBS/KP-LC/KPL
160302S/KPL 160424S vaccination (n = 20/group for PBS or KP-LC or KPL
160302S; n = 19/group for KPL 160424S), long term survival was monitored.
Kaplan-Meier survival analysis followed by Log rank (Mantel-Cox) tests was
used to determine significance. (D) KP mice were treated with the KP-LC
VIReST regime with or without CD8+ T cell depletion and survival monitored
as above (n = 20/group for PBS or KP-LC; n = 8/group for depletion). (E) KP
mice were treated with the KP-LC VIReST regime with or without CD4+ T cell
depletion and survival monitored as above (n = 20/group for PBS or KP-LC; n
= 8/group for depletion). (F) KP mice were treated with the KP-LC VIReST
regime with or without additional α-PD1 treatment and survival monitored as
above (n = 20/group for PBS or KP-LC; n = 8/group for α-PD1 treatment).
Kaplan-Meier survival analysis followed by Log rank (Mantel-Cox) tests was
used to determine significance. (G) Sera of immunized mice and control mice
were analyzed by ELISA for presence of ANAs. *p < 0.05, **p < 0.01,
***p < 0.001, and ns, no significance.
creating autologous cancer vaccines directly from stem cells (10).
Using two common driver mutations, KRASG12D and P53R172H,
we were able to replicate the transcriptome profile of cancer
cells isolated from transgenic mice in our stem cell derived
pancreatic cancer cells. Here, we extend this protocol to lung
cancer and importantly demonstrate that despite the use of the
same, albeit ubiquitous, driver mutations, the antigenic profile
of subsequent tumor cell lines was highly identical to lung
cancer cell lines from induced transgenic models, but not related
to pancreatic cancer cells derived in the same manner. This
demonstrates that the initiating mutations are less relevant to the
ensuing accrual of passenger mutations than the epigenetics and
lineage specialization of individual tumors. As driver mutations
can be expected to have low immunogenicity, these passenger
mutations must be key targets if vaccination strategies are to be
successful (10, 24). One of the most important aspects of this
vaccination regime is the ability to apply entirely autologous
vaccines early, or even prior to, disease development. Early
application will be the key to vaccine success, as antigen-specific
T cell induction can occur prior to selection of MHCI loss
of heterogeneity (LOH) variants, common in the evolution of
many cancers (25). It has previously been shown that a large
proportion of neoantigens were observed to bind to lost MHCI
haplotypes (26). Furthermore, recent evidence supports a model
of branched evolution in cancers that leads to variable, but
potentially considerable intra-tumoral heterogeneity in different
tumor types (27–29). This factor may be less relevant for lung
cancer vaccination strategies, as recent analysis suggests that 76%
of all mutations can be detected in all region of the tumor (9).
However, this characterization also revealed that accrual of non-
synonymous mutations occur as early events in the evolution of
cancer, thus early treatment potentially targets a large number of
immunogenic antigens, prior to immune suppression or evasion,
setting up an immune system capable of long-term control
of disease.
Early disease management is also vital for avoiding the
strongly immunosuppressive environment that occurs later
in disease evolution. Indeed, early pre-malignant lesions are
heavily infiltrated by immune cells with an activated phenotype
suggesting an ongoing anti-tumor response. At this stage,
immunosuppressive cells are considered rare (7). To maximize
the immunogenicity of the vaccine at this stage, we developed a
VIReST protocol, in which the stem cell derived cancer cells were
pre-infected with either AdV or VV prior to administration in
a prime-boost vaccination regime. Virus-infected cell vaccines,
whereby tumor cells are pre-infected with replicating tumor
tropic virus prior to delivery as a vaccine, has been shown
to provoke high levels of anti-tumor immunity that was not
achieved when cells were delivered without infection (23),
suggesting that replicating viruses can provide relevant danger
signals required for vaccine immunogenicity.We have previously
demonstrated that replicating viruses can provide adjuvant
danger signals and that sequential application of oncolytic AdV
followed by VV provides superior efficacy compared to use of
either virus alone or in the reverse order when administered
as therapeutics in animal tumor models (15) or as vaccine
adjuvants (10). We have also previously shown that the VIReST
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FIGURE 6 | Schematic of the VIReST regime applied for prophylactic prevention or therapeutic treatment of lung cancer. (A) A schematic of the VIReST regime and
how it has been applied in animal models of lung cancer is presented. (B) A schematic of how the proposed VIReST regime would be used clinically is presented.
regime is ineffective in a pancreatic cancer model when stem
cell-derived cancer cells are delivered without concomitant viral
infection (10).
Given that vaccine efficacy will be most prominent in
early stage or pre-malignant disease, a patient selection issue
arises. Lung cancers symptoms rarely appear until tumors are
at an advanced, often incurable stage. However, a number
of developments have led to the introduction of screening
techniques that can be applied to high risk individuals, including
Low-Dose Cat Scans (LCDT) that have been endorsed for
annual use to detect early signs of cancer (30, 31). In this
regard, use of personalized vaccine as an adjuvant to surgical
removal of pre-cancerous lesions can be envisaged. In addition,
circulating tumor DNA can be detected in the early-stage lung
cancers based on driver mutations (32, 33), and changes in gene
expression levels in the bronchial airway can be identified before
tumorigenesis (34, 35). These latter advances may also make
it possible to more accurately tailor VIReST to the individual,
by identification of driver mutations specific to the individual
that can be used to derive the lung cancer cells from iPSCs.
Patient tailored treatments will be vital for induction of long-
term efficacy, considering the role that environmental factors
play in the induction of lung tumors through a range of
driver mutations.
The results presented here suggest that it is feasible to
create personalized cancer cells from iPSCs without the need
for specimens from surgical biopsy, and these induced cancer
cells can mimic the original tumor, or potential tumor, to a
great extent. In addition to its use as an early-stage, or even
prophylactic, vaccine we also expect a role for this technology in
the detection of drug sensitivity of specific cancers in vitro.
To increase the efficiency of manufacture, it is possible to
source iPSCs with matched HLA molecules from iPSC stocks
(36) and safety concerns are addressed by preventing ongoing cell
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division using MMC treatment prior to application. No tumor
growth was observed at the inoculation site in any experiment
conducted and circulating ANA levels suggest no autoimmunity
was induced by the treatment.
In this study, we showed that KP-LC vaccine evokes
anti-tumor T cell responses using both subcutaneous tumor
and induced transgenic models of disease (Figure 6A) and
significantly extended the survival time of KP-LC vaccinated
mice, although notably did not prevent disease related death.
This suggests scope for improvement of the regime, that should
include optimizing the number of prime-boost cycles applied to
the patient andmore specific tailoring of iPSCs by introduction of
other driver mutations, particularly those associated with genetic
inheritance, including EGFR amongst others (37). It is worth
noting that vaccination produced by the lung cancer cell line KP-
LC derived from iPS cells or the lung cancer cell line KPL 160302S
derived from early lung cancer models can both significantly
prolong the survival of lung cancer mice, and their effect on
CD8+ T cells and CD4+ T cells infiltration are similar. These
two cell lines showed the highest similarities at the transcriptome
level and so we inferred that the lung cancer cell line induced
by iPS cells can largely mimic lung cancer cell lines from early
stage tumors. Interestingly, vaccination produced by the lung
cancer cell line KPL 160424S derived from advanced lung cancer
models cannot prolong the survival of mice and we speculate
that lung cancer cells derived from iPS cells or early staged lung
cancer had more immunogenic neo-antigens because they had
not been significantly screened or edited by the immune system
compared with the lung cancer cells from advanced lung cancer.
Interestingly, at the transcriptome level, several genes enriched
in cancer associated pathways were expressed more highly in KP-
LC than KPL 160424S. Thus, iPS cells can be used as a source
of cells for individualized preventive or therapeutic vaccination
and for the latter case will be extremely valuable when it is
difficult to obtain sufficient tumor cells from early stage cancers to
create personalized treatments. Further bioinformatical analysis
of the transcriptome data generated from this researchmay prove
invaluable in determining important antigen targets for future
vaccination strategies.
Immune checkpoint inhibition (ICI) has emerged as a
promising and powerful tool for cancer therapy and some lung
cancers have been shown to be sensitive to treatment with ICI
therapies clinically. Here we were unable to induce synergy when
combining VIReSTwith α-PD1 antibody therapy, suggesting that
ultimate treatment failure in our model was not due to PD1-PD-
L1-mediated T cell anergy. Indeed, while immune checkpoint
inhibition has been adopted for treatment of non-small cell
lung cancer (NSCLC), in fact only a small subset of patients
respond to treatment (38). Objective responses have been noted
to correlate with higher mutational burdens (39) or as a result of
involvement of specific driver mutations that result in induction
of PD-L1 expression within the TME (40). Thus, genetic analysis
of early stage disease may select patient populations expected
to respond more effectively to the combination of VIReST and
immune checkpoint blockade. There are however, a number of
alternative or complementary avenues for further exploration
of combination treatments that may improve regime efficacy,
including targeting TIM-3 and Lag-3, additional co-inhibitory
receptors known to be clinically significant in lung cancer escape
from immune control (41) or inhibition of TReg (42) and MDSC
suppressive cells (43) within the developing TME.
In summary, we have described a technological platform for
the development of highly antigenically related lung cancer cells
from iPSCs of healthy individuals and an effective vaccination
regime for prevention and treatment of lung cancer (Figure 6B).
These tumor cells were developed via introduction of common
tumor driver mutations, but the resulting antigenic profile was
not dependent on the driver mutation introduced, suggesting
that the epigenetics of an individual, specific to tissue lineage,
account for the pattern of neo-antigens expressed. Clearly the
situation in human patients is far more complex than reflected
in the mouse model used in this study and driving tumorigenesis
by introducing further driver mutations, to tailor iPSCs even
more accurately, is possible. This technology also has potential
for therapeutic use, after tumor resection where adequate viable
autologous material is not recovered, as a mechanism to prevent
tumor recurrence and metastasis after surgery. Determination
of patients for primary prophylactic use is more complex,
however identified high-risk individuals would be an obvious
population for targeted vaccination strategies. Ultimately, the
VIReST provides a safe and effective platform upon which to
create robust preventative vaccines that are personalized to be
most effective at preventing development or eliminating nascent
tumors and preventing their recurrence.
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